Minocycline to Treat Branch Retinal Vein Occlusion
Status:
Active, not recruiting
Trial end date:
2022-02-20
Target enrollment:
Participant gender:
Summary
Background:
- Branch retinal vein occlusion (BRVO) is a blockage of the small veins that carry blood away
from the retina in the back of the eye. It often leads to macular edema, a swelling of the
retina that is a common source of vision loss. Studies suggest that inflammation might be a
cause. Minocycline is a drug that might help prevent cells involved in inflammation from
becoming activated. It is approved for use as an antibiotic, but it has not yet been tested
to see if it can treat BRVO.
Objectives:
- To test the safety and effectiveness of minocycline as a treatment for branch retinal vein
occlusion.
Eligibility:
- Individuals at least 18 years of age who have branch retinal vein occlusion in at least one
eye, with vision between 20/32 and 20/200.
Design:
- This study lasts 2 years, with at least 25 visits. Participants must agree to protect
themselves from sunlight or artificial ultraviolet rays while in this study.
- Participants will be screened with a physical exam and medical history. They will also
have blood tests and an eye exam. One eye will be selected as the study eye to receive
the medicine.
- Those in the study will take minocycline or a placebo pill twice a day, about 12 hours
apart, for 2 years.
- Participants will have monthly visits for blood tests and full eye exams to study the
effect of the treatment. Other exams may include thyroid tests and eye imaging studies.
Those in the study may also receive injections of a drug to prevent the growth of new
blood vessels in the eye.